PT2900269T - Combinação de regorafenib e ácido acetilsalicílico para o tratamento de cancro colorretal - Google Patents

Combinação de regorafenib e ácido acetilsalicílico para o tratamento de cancro colorretal

Info

Publication number
PT2900269T
PT2900269T PT13770659T PT13770659T PT2900269T PT 2900269 T PT2900269 T PT 2900269T PT 13770659 T PT13770659 T PT 13770659T PT 13770659 T PT13770659 T PT 13770659T PT 2900269 T PT2900269 T PT 2900269T
Authority
PT
Portugal
Prior art keywords
regorafenib
combination
colorectal cancer
acetylsalicylic acid
treating colorectal
Prior art date
Application number
PT13770659T
Other languages
English (en)
Portuguese (pt)
Inventor
Ziegelbauer Karl
Weber Olaf
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2900269(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of PT2900269T publication Critical patent/PT2900269T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT13770659T 2012-09-25 2013-09-23 Combinação de regorafenib e ácido acetilsalicílico para o tratamento de cancro colorretal PT2900269T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12185852 2012-09-25

Publications (1)

Publication Number Publication Date
PT2900269T true PT2900269T (pt) 2018-10-22

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13770659T PT2900269T (pt) 2012-09-25 2013-09-23 Combinação de regorafenib e ácido acetilsalicílico para o tratamento de cancro colorretal

Country Status (29)

Country Link
US (1) US10898500B2 (enExample)
EP (1) EP2900269B1 (enExample)
JP (1) JP6294888B2 (enExample)
KR (1) KR102210575B1 (enExample)
CN (1) CN104994876A (enExample)
AU (1) AU2013322854B2 (enExample)
BR (1) BR112015006686B1 (enExample)
CA (1) CA2885688C (enExample)
CL (1) CL2015000744A1 (enExample)
CY (1) CY1120939T1 (enExample)
DK (1) DK2900269T3 (enExample)
EA (1) EA032023B1 (enExample)
ES (1) ES2687985T3 (enExample)
HK (1) HK1214169A1 (enExample)
HR (1) HRP20181462T1 (enExample)
HU (1) HUE039878T2 (enExample)
IL (1) IL237690B (enExample)
LT (1) LT2900269T (enExample)
MX (1) MX357035B (enExample)
MY (1) MY183969A (enExample)
NZ (1) NZ705860A (enExample)
PH (1) PH12015500587A1 (enExample)
PL (1) PL2900269T3 (enExample)
PT (1) PT2900269T (enExample)
RS (1) RS57875B1 (enExample)
SG (2) SG11201501963RA (enExample)
SI (1) SI2900269T1 (enExample)
WO (1) WO2014048881A1 (enExample)
ZA (1) ZA201502840B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
HRP20191937T1 (hr) 2012-09-25 2020-01-10 F. Hoffmann - La Roche Ag Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
LT3074400T (lt) 2013-11-26 2018-02-12 F. Hoffmann-La Roche Ag Oktahidro-ciklobuta [1,2-c;3,4-c`]dipirolo dariniai kaip autotaksino inhibitoriai
EA037928B1 (ru) 2014-03-26 2021-06-08 Ф. Хоффманн-Ля Рош Аг Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
PE20161223A1 (es) 2014-03-26 2016-11-12 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa)
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学(上海)有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX377277B (es) 2015-09-04 2025-03-07 Hoffmann La Roche Derivados de fenoximetilo.
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
DK3474858T3 (da) * 2016-06-28 2021-11-22 Asamedic As Tokomponentsammensætning omfattende acetylsalicylsyre
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
BR112019019017A2 (pt) 2017-03-16 2020-04-14 Hoffmann La Roche compostos heterocíclicos de utilidade como inibidores duplos de atx/ca
HUE066487T2 (hu) * 2017-06-02 2024-08-28 Bayer Healthcare Llc Regorafenib és nivolumab kombinációja rák kezelésére
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620834B1 (en) * 1999-07-02 2003-09-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
WO2007054303A2 (en) * 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Also Published As

Publication number Publication date
CY1120939T1 (el) 2019-12-11
IL237690B (en) 2019-07-31
EP2900269B1 (en) 2018-08-01
DK2900269T3 (en) 2018-10-01
JP6294888B2 (ja) 2018-03-14
PL2900269T3 (pl) 2019-02-28
IL237690A0 (en) 2015-05-31
WO2014048881A1 (en) 2014-04-03
SI2900269T1 (sl) 2018-10-30
LT2900269T (lt) 2018-11-12
NZ705860A (en) 2018-07-27
SG10201702356VA (en) 2017-04-27
US10898500B2 (en) 2021-01-26
MY183969A (en) 2021-03-17
EP2900269A1 (en) 2015-08-05
ZA201502840B (en) 2017-11-29
CA2885688C (en) 2021-03-02
BR112015006686B1 (pt) 2022-04-05
ES2687985T3 (es) 2018-10-30
HRP20181462T1 (hr) 2018-11-02
BR112015006686A2 (pt) 2019-08-27
US20150202214A1 (en) 2015-07-23
AU2013322854A1 (en) 2015-04-02
HUE039878T2 (hu) 2019-02-28
PH12015500587A1 (en) 2015-05-11
CN104994876A (zh) 2015-10-21
RS57875B1 (sr) 2018-12-31
CL2015000744A1 (es) 2016-01-08
CA2885688A1 (en) 2014-04-03
SG11201501963RA (en) 2015-04-29
HK1214169A1 (zh) 2016-07-22
JP2015529234A (ja) 2015-10-05
MX2015003728A (es) 2015-09-23
EA032023B1 (ru) 2019-03-29
KR20150060869A (ko) 2015-06-03
EA201500365A1 (ru) 2015-08-31
MX357035B (es) 2018-06-25
AU2013322854B2 (en) 2018-07-19
KR102210575B1 (ko) 2021-02-02

Similar Documents

Publication Publication Date Title
HUE039878T2 (hu) Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére
IL288181A (en) Cancer treatment methods
PL2818483T3 (pl) Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
LT2925888T (lt) Vėžio gydymo kompozicijos ir būdai
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL234640A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
IL234639A0 (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
IL234641B (en) Cancer treatment with rapamycin target site kinase inhibitors
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF